Last reviewed · How we verify
Gefitinib and Pemetrexed/platinum
This combination uses gefitinib to inhibit EGFR signaling in lung cancer cells while pemetrexed/platinum chemotherapy provides additional cytotoxic activity through multiple mechanisms.
This combination uses gefitinib to inhibit EGFR signaling in lung cancer cells while pemetrexed/platinum chemotherapy provides additional cytotoxic activity through multiple mechanisms. Used for Non-small cell lung cancer (NSCLC) with EGFR mutations.
At a glance
| Generic name | Gefitinib and Pemetrexed/platinum |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | EGFR tyrosine kinase inhibitor combined with antifolate and platinum-based chemotherapy |
| Target | EGFR (gefitinib); thymidylate synthase, dihydrofolate reductase (pemetrexed); DNA (platinum agents) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gefitinib is a tyrosine kinase inhibitor that blocks epidermal growth factor receptor (EGFR) signaling, particularly effective in EGFR-mutant non-small cell lung cancers. Pemetrexed is an antifolate that inhibits multiple enzymes in nucleotide synthesis, and platinum agents (cisplatin or carboplatin) cause DNA crosslinking and damage. The combination leverages targeted therapy with conventional chemotherapy for enhanced anti-tumor effect.
Approved indications
- Non-small cell lung cancer (NSCLC) with EGFR mutations
Common side effects
- Rash/acneiform dermatitis
- Diarrhea
- Nausea/vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
- Interstitial lung disease
- Hepatotoxicity
Key clinical trials
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (PHASE2)
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PHASE2)
- Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) (PHASE1, PHASE2)
- Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer (PHASE3)
- A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (PHASE3)
- PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
- Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC (PHASE2)
- A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gefitinib and Pemetrexed/platinum CI brief — competitive landscape report
- Gefitinib and Pemetrexed/platinum updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI